Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 141,536 shares of CYTK, which is worth approximately $9.4 Million. The most recent transaction as insider was on Dec 22, 2025, when has been sold 1,016 shares (Common Stock) at a price of $62.72 per share, resulting in proceeds of $63,723. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 142K

0.66% 3M change

21.94% 12M change

Total Value Held $9.4 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 22 2025	SELL Payment of exercise price or tax liability	$63,723 $62.72 p/Share	1,016 Reduced 0.71%	141,536 Common Stock
Dec 22 2025	BUY Grant, award, or other acquisition	-	4,000 Added 2.73%	142,552 Common Stock
Dec 16 2025	SELL Open market or private sale	$134,728 $61.24 p/Share	2,200 Reduced 1.56%	138,552 Common Stock
Dec 16 2025	BUY Exercise of conversion of derivative security	$23,320 $10.6 p/Share	2,200 Added 1.54%	140,752 Common Stock
Dec 03 2025	SELL Payment of exercise price or tax liability	$133,811 $65.02 p/Share	2,058 Reduced 1.46%	138,552 Common Stock
Dec 02 2025	SELL Open market or private sale	$140,558 $63.89 p/Share	2,200 Reduced 1.54%	140,610 Common Stock
Dec 02 2025	BUY Exercise of conversion of derivative security	$23,320 $10.6 p/Share	2,200 Added 1.52%	142,810 Common Stock

Nov 18 2025	SELL Open market or private sale	$146,190 $66.45 p/Share	2,200 Reduced 1.54%	140,610 Common Stock
Nov 18 2025	BUY Exercise of conversion of derivative security	$23,320 $10.6 p/Share	2,200 Added 1.52%	142,810 Common Stock
Nov 04 2025	SELL Open market or private sale	$136,667 $59.55 p/Share	2,295 Reduced 1.61%	140,610 Common Stock
Nov 04 2025	BUY Exercise of conversion of derivative security	$24,327 $10.6 p/Share	2,295 Added 1.58%	142,905 Common Stock
Oct 21 2025	SELL Open market or private sale	$122,553 $58.22 p/Share	2,105 Reduced 1.47%	140,610 Common Stock
Oct 21 2025	BUY Exercise of conversion of derivative security	$22,313 $10.6 p/Share	2,105 Added 1.45%	142,715 Common Stock
Oct 07 2025	SELL Open market or private sale	$121,120 $60.56 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Oct 07 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Sep 23 2025	SELL Open market or private sale	$98,560 $49.28 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Sep 23 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Sep 09 2025	SELL Open market or private sale	$102,580 $51.29 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Sep 09 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Aug 19 2025	SELL Open market or private sale	$76,620 $38.31 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Aug 19 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Aug 05 2025	SELL Open market or private sale	$72,680 $36.34 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Aug 05 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock
Jul 22 2025	SELL Open market or private sale	$74,940 $37.47 p/Share	2,000 Reduced 1.4%	140,610 Common Stock
Jul 22 2025	BUY Exercise of conversion of derivative security	$21,200 $10.6 p/Share	2,000 Added 1.38%	142,610 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM